This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The UK 100 is holding positive territory, but only just, as traders return from a long weekend. Buoying sentiment is more M&A (healthcare, challenger banks) and positive China trade data supporting Miners. However, investors are also alert to the risk of Trump ditching the Iran nuclear deal. GBP remains depressed, flattering the index amid Brexit & Overestimate uncertainty, although the latest leg lower for GBP/USD is more a function of USD strength than GBP weakness.
Contributors: UK Index +5pts; out-sized positive contributions from ULVR (share buyback), Shire (takeover bid), LLOY (technical rebound) and AZN (Seroquel licensing, Lynparza approval). These, however, are being offset by a big drag from BP/RDSb (heavyweights, oil off highs), HSBC (Goldman highlights Q1 costs), GSK (better news for AZN & SHP), STAN (still digesting Q1 results), BATS (bond proxies still being shunned) and VOD (range-bound).
Technicals: UK 100 back from a flirt with a breakout above 7600. April uptrend towards 7800 record highs still valid, but angle of ascent slowed. Channel floor still valid at 7535.
Click below to expand sections for more detailed analysis
UK 100 back from a flirt with a breakout above 7600. April uptrend towards 7800 record highs still valid, but angle of ascent slowed. Channel floor still valid at 7535.
Watch levels: Bullish 7580, Bearish 7560
Solid Green line
Possible support
Solid Red line
Possible resistance
Important: The information provided above does not constitute advice or opinion and must only be regarded as technical observations.
Click here for help with Support & Resistance Click here for help with technicals
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research